My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Resolution 2024-069
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
Resolution 2024-069
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
5/22/2024 9:25:50 AM
Creation date
5/22/2024 9:24:53 AM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
130
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
OPIOID ABATEMENT STRATEGIES <br />PART ONE: TREATMENT <br />A. TREAT OPIOID USE DISORDER (Ot]D) <br />Support fieatment of Opioid Use Disorder (OLJD) and any co-occurring Substance Use <br />Disorder or Mental Health (SLID/MH) conditions, co-usage, and/or co-addiction through <br />evidence-based, evidence-informed, or promising programs or strategies that may include, <br />but are not limited to, the following: <br />1. Expand availability of treatment for OUD and any co-occurring SUD/IvIH conditions, <br />co-usage, and/or co-addiction, including all forms of Medication-Assisted Treatment <br />(MAT) approved by the U.S. Food and Drug Administration. <br />2. Support and reimburse services that include the fuIl American Society of Addiction <br />Medicine (ASAM) continuum of care for OUD and any co-occurring SUD/MH <br />conditions, co-usage, and/ or co-addiction, including but not limited to : <br />a. Medication-Assisted Treatment (MAT); <br />b. Abstinence-based treatment; <br />c. Treatment, recovery, or other services provided by states, subdivisions, <br />community health centers; non-for-profit providers; or for-profit providers; <br />d. Treatment by providers that focus on OUD treatment as well as treatment by <br />providers that offer OUD treatment along with treatment for other SUD/IvIH <br />conditions, co-usage, and/or co-addiction; or <br />e. Evidence-informed residential services programs, as noted below. <br />3, Expand telehealth to increase access to treatment for OUD and any co-occurring <br />SUDA4H conditions, co-usage, and/or co-addiction, including MAT, as well as <br />counseling, psychiatric support, and other ffeatment and recovery support services. <br />4. Improve oversight of Opioid Treatment Programs (OTPs) to assure evidence-based, <br />evidence-informed, or promising practices such as adequate methadone dosing. <br />5. Support mobile intervention, freatment, and recovery services, offered by qualified <br />professionals and service providers, such as peer recovery coaches, for persons with <br />OUD and any co-occutring SUD/IVIH conditions, co-usage, and/or co-addiction and <br />for persons who have experienced an opioid overdose. <br />6. Support treatment of mental health trauma resulting from the traumatic experiences of <br />the opioid user (e.g., violence, sexual assault, human trafficking, or adverse childhood <br />experiences) and family mernbers (e.g., surviving family members after an overdose <br />1 <br />H-l5
The URL can be used to link to this page
Your browser does not support the video tag.